Britain and America have concluded a landmark commercial pact that will keep no levies on British drug exports entering the US market.
The Terms of the Deal
As part of the deal, the UK has pledged to raise funding on medicines through the National Health Service (NHS). This pledge ensures that tariffs on these crucial exports will remain at zero for a timeframe of 36 months.
This deal comes after recent threats to significantly raise import taxes on branded drug products, with figures discussed up to one hundred percent.
"This agreement with the UK bolsters the international landscape for innovative medicines and introduces much-needed balance to U.S.–U.K. medicine commerce," a release declared.
Economic Impact
Medicines represent one of the UK's largest export categories to the United States, which is by far the largest market for leading companies like GSK and AstraZeneca.
Trade data show that in the one-year period leading up to the third quarter, the UK sold medicines totaling £11.1bn to the US. This value represented nearly one-fifth of British export trade in that span.
"This agreement safeguards employment, increases investment and paves the way for the UK to emerge as a global hub for biotech and pharma," a government official remarked.
Specific NHS Changes
The pact entails several notable commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it judges new treatments to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a target to increase total health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount drug companies must refund to the NHS to prevent overspending will be limited at fifteen percent. Previously, rebates were more than twenty percent.
Recent Tensions
The pact follows a protracted dispute between the drug companies and the ministers over spending levels and NHS adoption.
The disagreement were heightened by claims that US patients were paying a premium for the same drugs than consumers in the UK and Europe.
Over the last 18 months, several major manufacturing plans in the UK have been delayed or abandoned, while multi-billion-dollar investments have been pledged toward US facilities.
A senior figure stated that the NHS had to invest a greater share on medicines, noting that its spending on drugs had decreased as a percentage of its total funding over the last ten years.
